STOML2 regulates autophagy through the PARL/PINK1 pathway, thereby reducing the chemoresistance of pancreatic cancer. Overexpression of STOML2 as a targeted therapy may help sensitize gemcitabine in the future. The gene discussed is STOML2; the disease is familial pancreatic carcinoma.